Dr. Werbel is a physician-scientist who provides consultative care for patients at Johns Hopkins who experience infectious disease complications before and after organ transplant, as well as in the setting of solid tumors or blood cancers. His research with the Johns Hopkins Transplant Research Center uses a combination of epidemiological and laboratory methods to better personalize the prevention of infectious complications among patients with complex immunodeficiencies. This includes using national cohort studies and clinical trials to optimize the use of vaccines and other prophylactic therapies for high-risk immunosuppressed populations. Dr. Werbel is rated as a Distinguished provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). His top areas of expertise are COVID-19, Severe Acute Respiratory Syndrome (SARS), HIV/AIDS, and Hepatitis.

Daniel Brodie is an Intensive Care Medicine specialist and a Pulmonary Medicine provider in Baltimore, Maryland. Dr. Brodie is rated as a Distinguished provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). His top areas of expertise are Acute Respiratory Distress Syndrome (ARDS), COVID-19, Respiratory Acidosis, Lung Transplant, and Embolectomy.

Dr. Robin Avery is an infectious disease physician who joined the Johns Hopkins faculty in 2012, with two decades of experience in transplant infectious disease. She is a past chair of the American Society of Transplantation (AST) Infectious Disease Community of Practice, was a co-editor of the first edition of the AST ID Guidelines, and serves on a Guidelines Committee for the Infectious Disease Society of America (IDSA) on immunizations in the immunocompromised host. She was the founding head of the Transplant Infectious Disease Section at the Cleveland Clinic and served as the founding director of the Cleveland Clinic Transplant ID Special Fellowship, authoring a curriculum that served as the basis for curricula later endorsed by the AST and IDSA. Her clinical and research interests include pre-transplant donor and recipient evaluation, and prevention and treatment of post-transplant infections, particularly transplant-associated viruses, viral load monitoring, novel therapies for CMV, hypogammaglobulinemia, immunizations, and strategies for safer living post-transplant. She has a strong interest in patient education and co-authored the script for a video designed to educate patients on decreasing post-transplant infection risks. Dr. Avery is rated as a Distinguished provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). Her top areas of expertise are Cytomegalic Inclusion Disease, Cytomegalovirus Infection, COVID-19, and Sepsis.

Dr. Yukari Manabe is a Professor in the Division of Infectious Diseases in the Department of Medicine with secondary appointments in the Bloomberg School of Public Health Department of International Health and the Department of Microbiology and Molecular Immunology. Dr. Manabe began her career working on the basic science aspects of tuberculosis (TB) immunopathogenesis in comparative animal models of infection, particularly latency, reactivation, and immune reconstitution inflammatory syndrome (IRIS) in the rabbit model within the Johns Hopkins Center for Tuberculosis Research. In 2007, she was seconded to the Infectious Diseases Institute (IDI) at Makerere College of Health Sciences as the Associate Medical Laboratory Director of the College of American Pathologists certified Makerere University-Johns Hopkins University Clinical Core Lab to study antiretroviral associated TB and IRIS. She then became the Head of Research at the IDI in 2008 until 2012 where she built research capacity and infrastructure to train Ugandan investigators. Since returning to Hopkins, she has become the PI of the Johns Hopkins POC STD Center (U54 funded through NIH) which is part of the newly formed Johns Hopkins Center for Innovative Diagnostics for Infectious Diseases. The Center develops new diagnostics, funds development for point-of-care diagnostics, evaluates (validation and verification) new technology, and performs pre-clinical studies to accelerate the development of infectious disease assays (STIs, TB, acute febrile illness, HIV, syphilis, viral hepatitis). Dr. Manabe is particularly interested in rapid, point-of-care infectious disease diagnostics suitable for the resource-limited settings particularly in sub-Saharan Africa (SSA). Her research has focused on accuracy testing of various rapid, point-of-care diagnostics for HIV and related infectious diseases of clinical importance in SSA. Studies have ranged from evaluations of performance accuracy through clinical implementation science studies on the patient-centered outcomes and impactful use of new rapid diagnostics. Dr. Manabe obtained her undergraduate degree from Yale University and her M.D. from Columbia University College of Physicians and Surgeons. After completing both her residency in Internal Medicine and fellowship in Infectious Diseases at Johns Hopkins Hospital, she joined the faculty in 1999. Dr. Manabe is rated as a Distinguished provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). Her top areas of expertise are HIV/AIDS, Cryptococcosis, Gonorrhea, Meningitis, and Tissue Biopsy.

Dr. Hager is a specialist in Critical Care Medicine. He is an expert in the diagnosis and management of all forms of acute respiratory failure, including asthma, pneumonia, C.O.P.D., neuromuscular diseases, and the acute respiratory distress syndrome. He also has extensive experience in the management of other life-threatening conditions such as pulmonary embolism, gastrointestinal hemorrhage, shock from sepsis, hypovolemia, and heart disease, and metabolic emergencies such as diabetic ketoacidosis and hyperosmolar states. Dr. Hager is rated as a Distinguished provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). His top areas of expertise are Severe Acute Respiratory Syndrome (SARS), COVID-19, Acute Respiratory Distress Syndrome (ARDS), and Cerebral Hypoxia.

Kathleen Neuzil is an Infectious Disease provider in Baltimore, Maryland. Dr. Neuzil is rated as a Distinguished provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). Her top areas of expertise are Typhoid Fever, Salmonella Enterocolitis, Flu, and COVID-19.

Theodore Iwashyna is a Pulmonary Medicine provider in Baltimore, Maryland. Dr. Iwashyna is rated as an Advanced provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). His top areas of expertise are Acute Respiratory Distress Syndrome (ARDS), Severe Acute Respiratory Syndrome (SARS), Cerebral Hypoxia, and COVID-19.

Dr. Kelly Gebo is a graduate of The Johns Hopkins University School of Medicine. She also earned an MPH in Epidemiology from The Johns Hopkins Bloomberg School of Public Health. She completed residency training in Internal Medicine at The Johns Hopkins Hospital followed by an infectious diseases fellowship and two additional years of fellowship training as a Robert Wood Johnson Clinical Scholar, also at Hopkins. Her clinical and research interests include clinical outcomes and healthcare utilization research within infectious diseases. She was Director of the JHU Public Health Studies Program between the Krieger School for Arts and Sciences and the Bloomberg School for Public Health, was an American Council of Education Fellow (hosted at the University of Pennsylvania) and was the inaugural Vice Provost for Education at Johns Hopkins. She was on sabbatical at Stanford University School of Medicine 2019-20 and served as the Chief Medical and Scientific Officer for the All of Us Research Program 2018-2020. She currently serves as the director of the Johns Hopkins Clinical Research Scholars Program and is Deputy Director of the Johns Hopkins Institute for Clinical and Translational Research. She has mentored undergraduate, public health and medical students, trainees, and junior faculty on infectious diseases and health services projects. She has authored or co-authored numerous chapters and over 250 papers. She is a member of the American Society of Clinical Investigation and has been awarded the David Levine Prize for mentoring at Johns Hopkins. LinkedIn https://www.linkedin.com/in/kelly-gebo-13377811/. Dr. Gebo is rated as an Advanced provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). Her top areas of expertise are HIV/AIDS, Myelitis, AIDS Dysmorphic Syndrome, and AIDS Dementia Complex.

Matthew Robinson, MD, is Assistant Professor in the Division of Infectious Diseases at Johns Hopkins University School of Medicine. He is interested in leveraging diagnostic innovation and precision medicine to reduce diagnostic and prognostic uncertainty for infectious diseases. His current projects include applications in global health, antimicrobial resistance, antibiotic stewardship, infection control, COVID-19, acute febrile illness, and tuberculosis. After undergraduate and medical school at Northwestern University, he completed internal medicine residency at New York University and Infectious Diseases fellowship at Johns Hopkins School of Medicine. During medical school, he worked at the Chinese Center for Disease Control and Prevention in Beijing, China under a Doris Duke International Clinical Research Fellowship. He also served as a clinician educator in internal medicine in Gulu, Uganda at the Gulu University Faculty of Medicine as a Global Health Service Partnership volunteer. As a fellow, he pursued a Fogarty Global Health Fellowship in Pune, India and an Antibacterial Resistance Leadership Group Fellowship. Since joining the faculty in 2019, Dr. Robinson has been supported by the Centers for Disease Control and Prevention, National Institutes of Health, and Food and Drug Administration. The focus of his work in antimicrobial resistance, antibiotic stewardship, infection control has been to characterize drug-resistant Gram-negative infections in India. His work with the Johns Hopkins Precision Medicine Center of Excellence for COVID-19 has included applying machine learning and causal inference techniques to predict COVID-19 outcomes. He has contributed to SARS-CoV-2 diagnostic development through the NIH Rapid Acceleration of Diagnostics (RADx) initiative and through collaborative development of other novel diagnostics. Dr. Robinson is rated as an Advanced provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). His top areas of expertise are Severe Acute Respiratory Syndrome (SARS), COVID-19, Togaviridae Disease, and Dengue Fever.

Dr. Joel Blankson is an associate professor of medicine at the Johns Hopkins University School of Medicine. He also holds an appointment in molecular and comparative pathobiology. His areas of clinical expertise include HIV pathogenesis and infectious disease. Dr. Blankson earned his M.D. from Cornell University Medical College and his Ph.D. from Rockefeller University. He completed his residency and a fellowship in infectious disease at Johns Hopkins. His research interests include the natural control of HIV-1 infection. Dr. Blankson is rated as an Advanced provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). His top areas of expertise are HIV/AIDS, Myelitis, AIDS Dementia Complex, and AIDS Dysmorphic Syndrome.

Dr. Annie Antar is an assistant professor of medicine at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include internal medicine and infectious diseases. Her areas of research expertise include long COVID, long COVID in people living with HIV, HIV cure, and suboptimal CD4 response after antiretroviral therapy. Dr. Antar earned her undergraduate degree from Harvard University and her M.D. and Ph.D. degrees from Vanderbilt University School of Medicine. She completed both her residency in internal medicine and fellowship in infectious diseases at the Johns Hopkins Hospital. Dr. Antar is rated as an Advanced provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). Her top areas of expertise are Long Haul COVID, Severe Acute Respiratory Syndrome (SARS), COVID-19, and HIV/AIDS.

Dr. Aaron M. Milstone is a professor of pediatrics at the Johns Hopkins University School of Medicine. He holds a joint appointments in Epidemiology and Health Policy and Management at the Bloomberg School of Public Health. A pediatric epidemiologist, Dr. Milstone specializes in treating infectious diseases in children. He serves as an associate hospital epidemiologist at The Johns Hopkins Hospital and the pediatric lead for infection prevention for the Johns Hopkins Health System. Dr. Milstone earned his medical degree from Yale University School of Medicine. He completed both a pediatrics residency and a research fellowship in pediatric infectious diseases at Children's Hospital of Philadelphia. He also completed a pediatric infectious diseases fellowship at Johns Hopkins. He holds a M.H.S. (Graduate Training Program in Clinical Investigation) from the Johns Hopkins Bloomberg School of Public Health and Johns Hopkins University School of Medicine. Dr. Milstone joined the Johns Hopkins faculty in 2007. His research interests focus on antibiotic resistance and prevention of healthcare-associated infections. He had led numerous clinical trials including the Pediatric SCRUB Trial and TREAT PARENTS Trial testing strategies to prevent organism transmission and healthcare-associated infections. He is principal investigator of the BrighT STAR Collaborative, guiding hospitals nationwide to reduce over-testing as a strategy to reduce antibiotic use and resistance. Dr. Milstone is a fellow of the American Academy of Pediatrics, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society for Healthcare Epidemiology of America. His many other professional honors include the Pediatric Infectious Diseases Society’s 2014 Young Investigator Award, the inaugural 2013 Caroline B. Hall Clinical Innovation Award, and the Society for Healthcare Epidemiology of America 2018 Mentor Scholar Award, and 2023 Johns Hopkins Medicine Armstrong Award for Excellence in Quality & Safety. Dr. Milstone is rated as an Advanced provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). His top areas of expertise are Sepsis, Methicillin-Resistant Staphylococcus Aureus (MRSA), Severe Acute Respiratory Syndrome (SARS), and Neonatal Sepsis.

Dr. Thomas Quinn is professor of medicine and pathology in the Johns Hopkins School of Medicine and professor of international health, epidemiology, and molecular microbiology and immunology in The Johns Hopkins School of Public Health, and professor of nursing in the Johns Hopkins School of Nursing. In 2006 he was appointed founding Director of the Johns Hopkins University Center for Global Health. He serves as advisor/consultant on HIV and STDs to the World Health Organization, Office of the Global AIDS Coordinator (PEPFAR), UNAIDS, and the FDA. He serves as Associate Director for International Research at the National Institute of Allergy and Infectious Diseases. He is a member of the Institute of Medicine of the National Academy of Sciences, and is a fellow of the American Association for the Advancement of Science. He is a fellow of the Infectious Diseases Society of America and a member of the American Association of Physicians. He is an author of over 900 publications on HIV, STDs, and infectious diseases, and serves on multiple editorial boards. Among his professional activities, Dr. Quinn is an alternate member of the Technical Panel of the Global Fund to Fight AIDS, Malaria, and Tuberculosis and has been on Advisor/Consultant on HIV and STDs to the World Health Organization, UNAIDS, and the U.S. Food and Drug Administration. In October 2004 he received membership in the Institute of Medicine. Dr. Quinn is rated as an Advanced provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). His top areas of expertise are HIV/AIDS, Genital Herpes, Chlamydia, and Human Papillomavirus Infection.

Dr. Christine Durand, associate professor of medicine and oncology and member of the Johns Hopkins Kimmel Cancer Center, is involved in clinical and translational research focused on individuals infected with HIV and hepatitis C virus who require cancer and transplant therapies. Her current research efforts include looking at outcomes of hepatitis C treatment after solid organ transplant, the potential use of organs from HIV-infected donors for HIV-infected solid organ transplant candidates, and HIV cure strategies including bone marrow transplantation. Dr. Durand is rated as an Advanced provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). Her top areas of expertise are HIV/AIDS, Hepatitis C, Hepatitis, Tissue Biopsy, and Nephrectomy.

Dr. Galiatsatos is a pulmonary and critical care medicine physician. He is an expert in the diagnosis and treatment of obstructive lung disease, tobacco cessation, and in the care of critically ill patients in the Medical ICU. He is a member of the Obstructive Lung Disease Group at Johns Hopkins, oversees the Tobacco Treatment Clinic and provides teaching to medical students and residents at Johns Hopkins. Dr. Galiatsatos is rated as an Advanced provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), COVID-19, Severe Acute Respiratory Syndrome (SARS), and Pneumonia.

Olivia Kates is an Infectious Disease provider in Baltimore, Maryland. Dr. Kates is rated as an Advanced provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). Her top areas of expertise are COVID-19, Diphtheria, Severe Acute Respiratory Syndrome (SARS), and Listeriosis.

Dr. Kathleen Page is a Professor of Medicine at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include infectious diseases, HIV/AIDS, substance use disorder. She received her undergraduate degree in public health from Johns Hopkins and earned her M.D. from Washington University School of Medicine. She completed her residency at the Hospital of the University of Pennsylvania and performed a fellowship in infectious diseases at Johns Hopkins. Dr. Page joined the Johns Hopkins faculty in 2006. Dr. Page is dedicated to improving access to high-quality care for underserved communities, including people living with HIV, migrants, and individuals with substance use disorders. Her research spans migrant health, infectious diseases, health and human rights, mobile health interventions, and implementation science. As the principal investigator on multiple grants, she leads studies on integrated care models for behavioral health, mHealth tools for HIV care, and strategies to increase equitable access to evidence-based health interventions. Dr. Page is Co-Director of the Center for Community and Global Health in Infectious Diseases (CCGHE-ID) whose mission is to improve health and equity, locally and abroad, through infectious diseases scientific research, training, advocacy, and service. Dr. Page is rated as an Advanced provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). Her top areas of expertise are HIV/AIDS, COVID-19, Severe Acute Respiratory Syndrome (SARS), and Hepatitis C.

A leading expert on brain injury, Dr. Daniel F. Hanley has been a professor of neurology, neurosurgery, and anesthesiology/critical care medicine at the Johns Hopkins University School of Medicine since 1996 and was named the Jeffrey and Harriet Legum Chair of Acute Care Neurology. Dr. Hanley founded and directed the Johns Hopkins Neurocritical Care Unit, one of the first critical care units dedicated solely to neurosurgical and neurological patients. Subsequently, in 1999, he founded and continues to direct the BIOS Clinical Trials Coordinating Center (BIOS CTCC), formerly known as the Division of Brain Injury Outcomes. Under Dr. Hanley’s leadership, BIOS CTCC, an academic contract research organization based at Johns Hopkins, has organized and completed more than 20 large clinical trials. He has been awarded over 70 clinical and basic research grants, predominantly from the National Institutes of Health and the FDA Orphan Products Grants Program. Dr. Hanley’s 40-year career in medicine has focused on clinical trial design, the organization and interpretation of drug and device trials, the development of strategic research plans, and FDA regulatory compliance. He has led international, NIH-sponsored trials including the MISTIE III and CLEAR III trials investigating minimally invasive neurosurgical techniques to treat hemorrhagic stroke. As principal investigator for the National Center for Advancing Translational Sciences (NCATS) Johns Hopkins Trial Innovation Center, Dr. Hanley leads collaborative efforts to advance education and therapeutics through innovative CTSA clinical trials. Currently, Dr. Hanley is the PI or multi-PI for several ongoing trials. These include a multisite phase 2/3 randomized controlled dementia prevention trial (MAP), a large multicenter clinical trial involving automated monitoring of atrial fibrillation (REACT AF), and a first-in-patient phase 2a biomarker and edema attenuation in intracerebral hemorrhage trial (BEACH). Dr. Hanley has published over 400 peer-reviewed articles and book chapters, received the Humboldt Research Prize for accomplishments in brain injury research, and mentored nearly 100 researchers. His trainees, which include a large number of trialists, have led 25 brain intensive care units, and over 40 have been named full professors, program leaders, or department chairs. He has served on public boards including the American Academy of Neurology, National Stroke Association, and NIH National Institute of Nursing Research. Dr. Hanley is rated as an Advanced provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). His top areas of expertise are Stroke, Hydrocephalus, Vertigo, Severe Acute Respiratory Syndrome (SARS), and Thrombectomy.

Dr. Gregory Kirk is a professor of medicine at the Johns Hopkins University School of Medicine. He holds joint appointments in oncology and, at the Johns Hopkins Bloomberg School of Public Health, in epidemiology. His areas of clinical expertise include epidemiology, hepatitis, HIV, AIDS and infectious diseases. He serves as the vice chair for clinical and translational research at the Johns Hopkins School of Medicine. Dr. Kirk received his undergraduate degree from Oklahoma State University. He earned a Ph.D. and M.P.H. from the Johns Hopkins Bloomberg School of Public Health. He earned his M.D. from the University of Oklahoma Health Sciences Center College of Medicine. He completed a residency in preventative medicine at the Johns Hopkins Bloomberg School of Public Health and in internal medicine at Georgetown University. He performed a fellowship in infectious diseases at the National Institute of Allergy and Infectious Diseases. His research focuses on understanding and preventing the long-term consequences of chronic HIV infection, particularly the malignant complications of HIV and viral hepatitis. He has extensive research and clinical experience in Africa, leading the Gambia Liver Cancer Study, one of the largest studies of hepatocellular carcinoma (HCC) performed in the continent, in addition to years of collaborative research in Uganda. Dr. Kirk pioneered the use of elastography and application of novel aflatoxin-associated biomarkers of HCC risk to be applied in Consortium projects. He has strong, multidisciplinary team leadership skills as principal investigator of the ALIVE cohort and several other collaborative studies in Baltimore. Dr. Kirk is rated as an Advanced provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). His top areas of expertise are HIV/AIDS, Hepatitis C, Hepatitis, and Hepatitis B.

Andrew Catanzaro is an Infectious Disease provider in Silver Spring, Maryland. Dr. Catanzaro is rated as an Experienced provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). His top areas of expertise are Scrofula, Lymphangitis, Cellulitis, and Pneumonia. Dr. Catanzaro is currently accepting new patients.